SE9201073D0 - Protein formulation - Google Patents

Protein formulation

Info

Publication number
SE9201073D0
SE9201073D0 SE9201073A SE9201073A SE9201073D0 SE 9201073 D0 SE9201073 D0 SE 9201073D0 SE 9201073 A SE9201073 A SE 9201073A SE 9201073 A SE9201073 A SE 9201073A SE 9201073 D0 SE9201073 D0 SE 9201073D0
Authority
SE
Sweden
Prior art keywords
pct
formulation
growth hormone
citrate
buffer substance
Prior art date
Application number
SE9201073A
Other languages
English (en)
Swedish (sv)
Inventor
S Castensson
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20385860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9201073(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Priority to SE9201073A priority Critical patent/SE9201073D0/xx
Publication of SE9201073D0 publication Critical patent/SE9201073D0/xx
Priority to PT93908252T priority patent/PT587858E/pt
Priority to ES93908252T priority patent/ES2150940T5/es
Priority to EP93908252A priority patent/EP0587858B2/en
Priority to US08/162,017 priority patent/US5567677A/en
Priority to CA002102693A priority patent/CA2102693C/en
Priority to AT93908252T priority patent/ATE196092T1/de
Priority to NZ251498A priority patent/NZ251498A/en
Priority to DK93908252T priority patent/DK0587858T3/da
Priority to JP51737893A priority patent/JP3268557B2/ja
Priority to PCT/SE1993/000281 priority patent/WO1993019776A1/en
Priority to AU39135/93A priority patent/AU666007B2/en
Priority to DE69329367T priority patent/DE69329367T3/de
Priority to NO19934355A priority patent/NO310804B1/no
Priority to GR20000402632T priority patent/GR3034925T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SE9201073A 1992-04-03 1992-04-03 Protein formulation SE9201073D0 (sv)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SE9201073A SE9201073D0 (sv) 1992-04-03 1992-04-03 Protein formulation
AU39135/93A AU666007B2 (en) 1992-04-03 1993-04-01 Protein formulation comprising growth hormone
DE69329367T DE69329367T3 (de) 1992-04-03 1993-04-01 Wachstumshormon-enthaltende proteinformulierung
CA002102693A CA2102693C (en) 1992-04-03 1993-04-01 Protein formulation comprising growth hormone
DK93908252T DK0587858T3 (da) 1992-04-03 1993-04-01 Væksthormonholdig proteinformulering
EP93908252A EP0587858B2 (en) 1992-04-03 1993-04-01 Protein formulation comprising growth hormone
US08/162,017 US5567677A (en) 1992-04-03 1993-04-01 Protein formulation comprising growth hormone
PT93908252T PT587858E (pt) 1992-04-03 1993-04-01 Formulacoes de proteinas contendo uma hormona de crescimento
AT93908252T ATE196092T1 (de) 1992-04-03 1993-04-01 Wachstumshormon-enthaltendeproteinformulierung
NZ251498A NZ251498A (en) 1992-04-03 1993-04-01 Injectable formulations of human growth hormone and citrate buffer
ES93908252T ES2150940T5 (es) 1992-04-03 1993-04-01 Formulacion proteinica que comprende hormona del crecimiento.
JP51737893A JP3268557B2 (ja) 1992-04-03 1993-04-01 成長ホルモンから成る蛋白調合物
PCT/SE1993/000281 WO1993019776A1 (en) 1992-04-03 1993-04-01 Protein formulation comprising growth hormone
NO19934355A NO310804B1 (no) 1992-04-03 1993-11-30 Stabilisert injiserbar formulering av humant veksthormon og fremgangsmåte for fremstilling derav
GR20000402632T GR3034925T3 (en) 1992-04-03 2000-11-28 Protein formulation comprising growth hormone.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9201073A SE9201073D0 (sv) 1992-04-03 1992-04-03 Protein formulation

Publications (1)

Publication Number Publication Date
SE9201073D0 true SE9201073D0 (sv) 1992-04-03

Family

ID=20385860

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9201073A SE9201073D0 (sv) 1992-04-03 1992-04-03 Protein formulation

Country Status (15)

Country Link
US (1) US5567677A (da)
EP (1) EP0587858B2 (da)
JP (1) JP3268557B2 (da)
AT (1) ATE196092T1 (da)
AU (1) AU666007B2 (da)
CA (1) CA2102693C (da)
DE (1) DE69329367T3 (da)
DK (1) DK0587858T3 (da)
ES (1) ES2150940T5 (da)
GR (1) GR3034925T3 (da)
NO (1) NO310804B1 (da)
NZ (1) NZ251498A (da)
PT (1) PT587858E (da)
SE (1) SE9201073D0 (da)
WO (1) WO1993019776A1 (da)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
DE19539574A1 (de) 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
AUPN801296A0 (en) 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
ZA9711731B (en) * 1996-12-31 1998-07-01 Monsanto Co Aqueous glycerol formulations of somatotropin
ZA9711733B (en) 1996-12-31 1998-07-01 Monsanto Co Method for solubilization and naturation of somatotropins
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
CA2378949C (en) * 1999-07-12 2015-03-31 Grandis Biotech Gmbh Growth hormone formulations
JP2004515467A (ja) 2000-08-07 2004-05-27 ネクター セラピューティックス 吸入可能な、噴霧乾燥した、最少の凝集物を有する４−ヘリックスバンドルタンパク質粉末
GB2371227A (en) * 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
US7271150B2 (en) * 2001-05-14 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
CA2475953A1 (en) * 2002-02-27 2003-09-04 E. Ann Tallant Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
US20070065469A1 (en) * 2002-07-09 2007-03-22 Michael Betz Liquid formulations with high concentration of human growth hormone (high) comprising glycine
CN1668332A (zh) * 2002-07-09 2005-09-14 桑多斯股份公司 包含苯酚的含高浓度人生长激素的液体制剂
EP1603588A2 (en) * 2003-03-18 2005-12-14 Ares Trading S.A. Stabilisation of growth hormones in solution
ES2383691T3 (es) 2003-12-23 2012-06-25 Pharmacia Corporation Formulación líquida estable de hormonas de crecimiento
UA89781C2 (uk) * 2004-04-07 2010-03-10 Арес Трейдінг С.А. Рідкий склад гормона росту
NZ552128A (en) 2004-08-03 2009-09-25 Transtech Pharma Inc Rage fusion proteins without Fc hinge region and methods of use
US20090060925A1 (en) * 2004-08-03 2009-03-05 The Trustees Of Columbia University In The City Of Rage Fusion Proteins and Methods of Use
JP4951344B2 (ja) * 2004-08-24 2012-06-13 第一三共株式会社 生理活性ペプチド液状製剤
EP1809663B1 (en) * 2004-11-09 2008-09-17 Ares Trading S.A. Method for purifying fsh
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
HUE038947T2 (hu) * 2005-08-26 2018-12-28 Ares Trading Sa Eljárás glikozilált béta-interferon elõállítására
US7947304B2 (en) 2005-11-02 2011-05-24 Transpharma Medical Ltd. Human growth hormone patch formulations
WO2007065918A2 (en) * 2005-12-09 2007-06-14 Ares Trading S.A. Method for purifying fsh or a fsh mutant
BRPI0620380B1 (pt) * 2005-12-23 2018-04-24 Gcoder Systems Ab Padrão de posicionamento
US20090004190A1 (en) * 2006-02-09 2009-01-01 Mjalli Adnan M M Rage Fusion Proteins And Methods Of Use
JP5558810B2 (ja) * 2006-05-05 2014-07-23 トランステック ファーマ，リミティド ライアビリティ カンパニー Ｒａｇｅ融合タンパク質、製剤及びその使用方法
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
MX2009012609A (es) 2007-05-22 2009-12-07 Amgen Inc Composiciones y metodos para producir proteinas de fusion bioactivas.
AU2008314689A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying an Fc-containing protein
WO2009053358A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying fc-fusion proteins
AU2010240569A1 (en) 2009-04-20 2011-10-20 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
US20120108512A1 (en) * 2009-05-07 2012-05-03 Novo Nordisk Health Care Ag Stable pharmaceutical compositions of peptide derivatized using an oxime linker
IN2012DN02861A (da) * 2009-11-17 2015-07-24 Ipsen Pharma Sas
KR101337797B1 (ko) 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
US10064951B2 (en) 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
CA2925416A1 (en) * 2013-09-27 2015-04-02 Hanmi Pharm. Co., Ltd. Sustained type human growth hormone preparation
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
WO2016011281A1 (en) * 2014-07-17 2016-01-21 Teva Pharmaceutical Industries Ltd. FORMULATIONS OF AN ALBUMIN-hGH FUSION PROTEIN

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
EP0189673B1 (en) * 1984-12-24 1990-09-26 Sumitomo Pharmaceuticals Company, Limited Stable growth hormone releasing factor preparation
EP0211601A3 (en) * 1985-07-30 1988-01-13 International Minerals And Chemical Corporation Stabilization of growth promoting hormones
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
DE3782737T3 (de) * 1987-08-21 1999-05-20 Imcera Group Inc., Northbrook, Ill. Stabilisierung von Wachstumshormonen.
US4837202A (en) † 1987-09-14 1989-06-06 Pitman-Moore, Inc. Method for stimulating the immune system
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH01308235A (ja) * 1988-06-03 1989-12-12 Yamanouchi Pharmaceut Co Ltd ヒト成長ホルモン経鼻剤
US5008244A (en) * 1989-05-15 1991-04-16 Pitman-Moore, Inc. Method for increasing fertility in animals
CA2020654A1 (en) * 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
IN172427B (da) * 1989-11-14 1993-07-24 Fidia Spa
US5217954A (en) * 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
WO1992017200A2 (en) * 1991-03-28 1992-10-15 Genentech, Inc. Stable growth hormone metal ion formulations
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
DE69322268T2 (de) * 1992-04-30 1999-08-05 Cor Therapeutics Inc Stabile zusammensetzung von polypeptiden
CA2489978A1 (en) * 1992-07-31 1994-02-17 Genentech, Inc. Human growth hormone aqueous formulation

Also Published As

Publication number Publication date
ATE196092T1 (de) 2000-09-15
DK0587858T3 (da) 2000-12-18
AU666007B2 (en) 1996-01-25
NZ251498A (en) 1995-07-26
NO934355L (no) 1993-12-01
CA2102693C (en) 2008-06-17
DE69329367T2 (de) 2001-06-21
NO934355D0 (no) 1993-11-30
DE69329367T3 (de) 2008-06-19
JP3268557B2 (ja) 2002-03-25
PT587858E (pt) 2001-02-28
EP0587858B1 (en) 2000-09-06
EP0587858B2 (en) 2007-11-14
AU3913593A (en) 1993-11-08
GR3034925T3 (en) 2001-02-28
WO1993019776A1 (en) 1993-10-14
JPH06508156A (ja) 1994-09-14
EP0587858A1 (en) 1994-03-23
DE69329367D1 (de) 2000-10-12
NO310804B1 (no) 2001-09-03
CA2102693A1 (en) 1993-10-04
US5567677A (en) 1996-10-22
ES2150940T5 (es) 2008-04-16
ES2150940T3 (es) 2000-12-16

Similar Documents

Publication Publication Date Title
SE9201073D0 (sv) Protein formulation
EP0747092A3 (en) Dissolution liquid for drug in iontophoresis
CA2275890A1 (en) Stable liquid interferon formulations
ATE175424T1 (de) Verfahren zur gewinnung von hochreinem von willebrand-faktor
DK0910399T3 (da) Stabilt farmaceutisk BDNF-præparat
NO883926L (no) Fremgangsmaate for fremstilling av stabilisert humanproteinpreparat.
DE3585556D1 (de) Pharmazeutische zusammensetzungen, welche ein dipeptid enthalten.
DE3587958D1 (de) Rekombinantes alveolares oberflächenaktives protein.
DK1017413T3 (da) Flydende formulering af interferon-beta
ES2187820T3 (es) Formulaciones farmaceuticas de factor de liberacion de la corticotrop ina que tiene una estabilidad en su forma liquida.
ATE218868T1 (de) Hustenhemmende, theobromine enthaltende zusammensetzungen
Li Recent studies on the problems involved in the preparation, properties and bioassay of adrenocorticotrophic hormone
Holbrook et al. The identification of a peptide in human parotid saliva particularly active in enhancing the glycolytic activity of the salivary micro-organisms.
DE3777845D1 (de) Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
NO934107D0 (no) Penetrasjonsfremmende substans
DK0641216T3 (da) Farmaceutisk præparat indeholdende IL-6
KR860006982A (ko) 안정한 감마 인터페론 제형의 제조방법
Donohue Jr et al. Glucose-6-phosphate dehydrogenase Partial characterization of the rat liver and uterine enzymes
Leaver Studies on certain peptide fractions isolated from human dentine
Lafeber Comparison of PTH and hypocalcin in mammalian and teleost bioassays
BR9006746A (pt) Peptideo fisiologicamente ativo e agente regulador do metabolismo de calcio